Neon Therapeutics Presents Data from NEO-PV-01’s Phase 1b Trial: Immune and Pathology Markers Associated with Durable Clinical Benefit in Metastatic Melanoma – CBI
Homepage/Press Release/Neon Therapeutics Presents Data from NEO-PV-01’s Phase 1b Trial: Immune and Pathology Markers Associated with Durable Clinical Benefit in Metastatic Melanoma
Press Release
Neon Therapeutics Presents Data from NEO-PV-01’s Phase 1b Trial: Immune and Pathology Markers Associated with Durable Clinical Benefit in Metastatic Melanoma
